Gastric Cancer

, Volume 9, Issue 2, pp 82–87 | Cite as

Chemotherapy sensitivity and resistance testing: to be “standard” or to be individualized, that is the question

  • Tetsuro Kubota
  • Larry Weisenthal
Review article


Radical surgery with extended lymph-node dissection is the treatment of first choice and the only curative treatment for locally advanced gastric cancer. While recent combination chemotherapy with S-1 (a combination of tegafur with two biomodulators, gimeracil and oteracil) has achieved high response rates, controversy still remains regarding the significance of adjuvant cancer chemotherapy after surgery. We have been applying chemosensitivity testing in evaluating the appropriate adjuvant cancer chemotherapy for advanced gastric cancer. Our multiple studies have indicated that this chemosensitivity testing would be useful to improve the results of adjuvant chemotherapy, by increasing survivals in the sensitive group. The chemosensitivity testing is approved as “advanced clinical medicine” by the Japanese Ministry of Health, Welfare, and Labor at 11 institutes at present. While complete lymph-node dissection and chemosensitivity test-guided adjuvant chemotherapy has been reported to result in a survival benefit for patients with advanced gastrointestinal cancer, the clinical utility of the testing should be established by means of prospective, randomized clinical trials. Two pivotal clinical trials have been initiated to clarify the utility of chemosensitivity testing in the selection of the appropriate adjuvant cancer chemotherapy for gastric cancer.

Key words

Chemosensitivity testing MTT assay Histoculture drug-response assay Gastric cancer Clinical trial 


  1. 1.
    Schipper, DL, Wagener, DJ 1996Chemotherapy of gastric cancerAnticancer Drugs713749PubMedGoogle Scholar
  2. 2.
    Macdonald, JS, Gohmann, JJ 1988Chemotherapy of advanced gastric cancer: present status, future prospectsSemin Oncol15429PubMedGoogle Scholar
  3. 3.
    Sakata, Y, Ohtsu, A, Horikoshi, N, Sugimachi, K, Mitachi, Y, Taguchi, T 1998Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patientsEur J Cancer34171520PubMedCrossRefGoogle Scholar
  4. 4.
    Koizumi, W, Kurihara, M, Nakano, S, Hasegawa, K 2000Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study GroupOncology581917PubMedCrossRefGoogle Scholar
  5. 5.
    Koizumi, W, Tanabe, S, Saigenji, K, Ohtsu, A, Boku, N, Nagashima, F,  et al. 2003Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancerBr J Cancer89220712PubMedCrossRefGoogle Scholar
  6. 6.
    Kondo, T, Kubota, T, Tanimura, T, Yamaue, H, Akiyama, S, Maehara, Y,  et al. 2000Cumulative results of chemosensitivity tests for antitumor agents in JapanAnticancer Res20238992Google Scholar
  7. 7. Scholar
  8. 8.
    Hermans, J, Bonenkamp, JJ, Boon, MC, Bunt, AMG, Ohyama, S, Sasako, M,  et al. 1993Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trialsJ Clin Oncol1114417PubMedGoogle Scholar
  9. 9.
    Pignon, JP, Ducreux, M, Rougier, P 1994Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisalJ Clin Oncol128778PubMedGoogle Scholar
  10. 10.
    Nakajima, T, Ohta, K, Ohyama, S, Hamajima, N 1999

    Meta-analysis of adjuvant chemotherapy trials for gastric cancer at the Cancer Institute Hospital

    Nakajima, TYamaguchi, T eds. Multimodality therapy for gastric cancerSpringer-VerlagHeidelberg Berlin New York Tokyo2731
    Google Scholar
  11. 11.
    Earle, CC, Maroun, JA 1999Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trialsEur J Cancer35105964PubMedCrossRefGoogle Scholar
  12. 12.
    Mari, E, Floriani, I, Tinazzi, A, Buda, A, Belfiglio, M, Valentini, M,  et al. 2000Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente)Ann Oncol1183743PubMedCrossRefGoogle Scholar
  13. 13.
    Janunger, KG Hafstroem, L Nygren, P Glimelius, B SBU-group. Swedish Council of Technology Assessment in Health Care2001A systematic overview of chemotherapy effects in gastric cancerActa Oncol4030926PubMedCrossRefGoogle Scholar
  14. 14.
    Panzini, I, Gianni, L, Fattori, PP, Tassinari, D, Imola, M, Fabbri, P,  et al. 2002Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analysesTumori88217PubMedGoogle Scholar
  15. 15.
    Japanese Gastric Cancer Association eds. 2001Guideline of gastric cancer therapy1st ed.KaneharaTokyoGoogle Scholar
  16. 16.
    Japanese Gastric Cancer Association eds. 2004Guideline of gastric cancer therapy2nd ed.KaneharaTokyoGoogle Scholar
  17. 17.
    Macdonald, JS, Smalley, SR, Benedetti, J, Hundahl, SA, Estes, NC, Stemmermann, GN,  et al. 2001Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junctionN Engl J Med34572530PubMedCrossRefGoogle Scholar
  18. 18.
    Kinoshita T, Nakajima T, Ohashi Y, National Surgical Adjuvant Study Group: Adjuvant chemotherapy with uracil-tegafur (UFT) for serosa negative advanced gastric cancer: results of a randomized trial by National Surgical Adjuvant Study of Gastric Cancer. Proc 41st ASCO, Abstract no. 4021; 2005. p. 313sGoogle Scholar
  19. 19.
    Cunningham D, Allum WH, Srtenning SP, Weeden S for the NCRI Upper GI Cancer Clinical Studies Group Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc 41st ASCO Abstract no. 4001; 2005. p. 308sGoogle Scholar
  20. 20.
    Saikawa, Y, Kubota, T, Furukawa, T, Suto, A, Watanabe, M, Kumai, K,  et al. 1994Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancerJpn J Cancer Res857625PubMedGoogle Scholar
  21. 21.
    Mosmann, T 1983Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assaysJ Immunol Methods655563PubMedCrossRefGoogle Scholar
  22. 22.
    Shimoyama, Y, Kubota, T, Watanabe, M, Ishibiki, K, Abe, O 1989Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to clonogenic assayJ Surg Oncol41128PubMedGoogle Scholar
  23. 23.
    Suto, A, Kubota, T, Shimoyama, Y, Ishibiki, K, Abe, O 1989MTT assay with reference to the clinical effect of chemotherapyJ Surg Oncol422832PubMedGoogle Scholar
  24. 24.
    Furukawa, T, Kubota, T, Suto, A, Takahara, T, Yamaguchi, H, Takeuchi, T,  et al. 1991Clinical usefulness of chemosensitivity testing using the MTT assayJ Surg Oncol4818893PubMedGoogle Scholar
  25. 25.
    Furukawa, T, Kubota, T, Watanabe, M, Takahara, T, Yamaguchi, H, Takeuchi, T,  et al. 1992High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end pointInt J Cancer5148998PubMedGoogle Scholar
  26. 26.
    Furukawa, T, Kubota, T, Watanabe, M, Kase, S, Takahara, T, Yamaguchi, H,  et al. 1992Chemosensitivity testing of clinical gastrointestinal cancers using histoculture and MTT endpointAnticancer Res12137782PubMedGoogle Scholar
  27. 27.
    Furukawa, T, Kubota, T, Hoffman, RM 1995Clinical applications of the histoculture drug response assayClin Cancer Res130511PubMedGoogle Scholar
  28. 28.
    Kubota, T, Sasano, N, Abe, O, Nakao, I, Kawamura, E, Saito, T,  et al. 1995Potential of the histoculture drug response assay to contribute to cancer patient survivalClin Cancer Res1153743PubMedGoogle Scholar
  29. 29.
    Lenz, HJ, Leichman, CG, Danenberg, KD, Danenberg, PV, Groshen, S, Cohen, H,  et al. 1996Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor of primary tumor response and overall survivalJ Clin Oncol1417682PubMedGoogle Scholar
  30. 30.
    Grau, JJ, Domingo-Domenrech, J, Morente, V, Pera, M, Garcia-Valdecasas, JC, Fuster, J,  et al. 2004Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafurOncology6622633PubMedCrossRefGoogle Scholar
  31. 31.
    Ishikawa, Y, Kubota, T, Otani, Y, Watanabe, M, Teramoto, T, Kumai, K,  et al. 2000Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracilJpn J Cancer Res9110512PubMedGoogle Scholar
  32. 32.
    Toriumi, F, Kubota, T, Saikawa, Y, Yoshida, M, Otani, Y, Watanabe, M,  et al. 2004Thymidylate synthetase genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric cancerAnticancer Res24245563PubMedGoogle Scholar
  33. 33.
    Terashima, M, Fujiwara, H, Takagane, A, Abe, K, Irinoda, T, Nakaya, T,  et al. 2003Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancerGastric Cancer67181PubMedCrossRefGoogle Scholar
  34. 34.
    Metzger, R, Leichman, CG, Danenberg, KD, Danenberg, PV, Lenz, HJ, Hayashi, K,  et al. 1998ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapyJ Clin Oncol1630916PubMedGoogle Scholar
  35. 35.
    Suganuma, K, Kubota, T, Saikawa, Y, Abe, S, Otani, Y, Furukawa, T,  et al. 2003Possible chemoresistance-related genes for gastric cancer detected by cDNA microarrayCancer Sci943559PubMedCrossRefGoogle Scholar
  36. 36.
    Fujita, K, Kubota, T, Matsusaki, SW, Otani, Y, Watanabe, M, Teramoto, T,  et al. 1998Further evidence for the value of the chemosensitivity test in deciding appropriate chemotherapy for advanced gastric cancerAnticancer Res1819738PubMedGoogle Scholar
  37. 37.
    Abe, S, Kubota, T, Matsuzaki, SW, Otani, Y, Watanabe, M, Teramoto, T,  et al. 1999Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer chemotherapy for stage III non-scirrhous gastric cancerAnticancer Res19458186PubMedGoogle Scholar
  38. 38.
    Kubota, T, Egawa, T, Otani, Y, Furukawa, T, Saikawa, Y, Yoshida, M,  et al. 2003Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal disseminationAnticancer Res235838PubMedGoogle Scholar
  39. 39.
    Samson, DJ, Seidenfeld, J, Ziegler, K, Aronson, N 2004Chemotherapy sensitivity and resistance assays: a systematic reviewJ Clin Oncol22361830PubMedCrossRefGoogle Scholar
  40. 40.
    Schrag, D, Garewal, HS, Burstein, HJ, Samson, DJ, Von Hoff, DD, Somerfield, MR 2004American Society of Clinical Oncology Technology Assessment. Chemotherapy sensitivity and resistance assaysJ Clin Oncol2236318PubMedCrossRefGoogle Scholar
  41. 41.
    Weisenthal LM, Nygren P. Current status of cell culture drug resistance testing (CCDRT). 2002. Scholar
  42. 42.
    Paik, S, Shak, S, Tang, G, Kim, C, Baker, J, Cronin, M,  et al. 2004A multigene assay to predict recurrence to tamoxifen-treated, node-negative breast cancerN Engl J Med351281726PubMedCrossRefGoogle Scholar
  43. 43.
    Cappuzzo, F, Varella-Garcia, M, Shigematsu, H, Domenichini, I, Bartolini, S, Ceresoli, GL,  et al. 2005Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patientsJ Clin Oncol23500718PubMedCrossRefGoogle Scholar
  44. 44.
    Kubota T. Chemosensitivity test for adjuvant cancer chemotherapy of gastric cancer (JACCRO GC-04). Igaku no Ayumi (J Clin Exp Med) 2006;217Google Scholar
  45. 45.
    Nomura E, Tanigawa N. JCOG clinical trial for evaluation of the utility of in vitro chemosensitivity test for cancer. Igaku no Ayumi (J Clin Exp Med) 2006;217Google Scholar

Copyright information

© International and Japanese Gastric Cancer Association 2006

Authors and Affiliations

  • Tetsuro Kubota
    • 1
  • Larry Weisenthal
    • 2
  1. 1.Center for Advanced and Comprehensive MedicineKeio University HospitalTokyoJapan
  2. 2.Weisenthal Cancer GroupHuntington BeachUSA

Personalised recommendations